Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

15/08	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
11/08	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI

Market Cap	2.66M 2.3M 2.17M 1.97M 3.7M 255M 3.72M 25.94M 10M 129M 9.98M 9.76M 411M	P/E 2024	-5.27x	P/E 2025	-3.28x
Enterprise Value	3.4M 2.94M 2.78M 2.52M 4.73M 326M 4.76M 33.18M 12.78M 165M 12.76M 12.48M 525M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

15/08	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
11/08	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI
04/08	Bioxytran, Inc. and University Of Minnesota Department Of Chemistry Execute Second Sponsored Research Agreement To Advance ASI-Powered Carbohydrate Drug Design Platform	CI
31/07	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE
29/07	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement	CI
16/07	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst	RE
16/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
05/03	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
03/03	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI

11/08	Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence	AQ
04/08	Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs	AQ
29/07	Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research	AQ
29/05	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
21/03	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	01/09/2018
Ola Soderquist DFI	Director of Finance/CFO	65	01/09/2018
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

US Rare Earth Minerals Inc Stock Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation: US Rare Earth Minerals Inc

Latest news: US Rare Earth Minerals Inc

Press Releases: US Rare Earth Minerals Inc

Managers and Directors: US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	02/11/2018
Alan Hoberman BRD	Director/Board Member	73	02/11/2018
David Platt CHM	Chairman	73	01/09/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+5.04%	+3.27%	+50.62%	+105.43%	66.93B
ARGENX SE	+1.64%	-2.89%	+34.67%	+80.49%	61.97B
INSMED INCORPORATED	-3.18%	+0.33%	-12.46%	+369.82%	28.26B
WUXI BIOLOGICS (CAYMAN) INC.	+4.55%	-0.08%	+34.70%	+17.28%	24.59B
BIONTECH SE	+2.20%	+0.20%	+1.00%	-13.14%	24.3B
GENMAB A/S	+1.15%	-2.26%	+17.56%	-16.53%	19.41B
PHARMAESSENTIA CORPORATION	-7.03%	-9.16%	+161.91%	+303.00%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.44%	-1.68%	-5.00%	+541.17%	14.18B
SUMMIT THERAPEUTICS INC.	+4.96%	+6.60%	-2.75%	+864.40%	14B
Average	+1.42%	-3.94%	+31.14%	+250.21%	30.05B
Weighted average by Cap.	+1.99%	-2.84%	+33.32%	+174.32%

	2024	2025
Net sales	-	-
Net income	-2.37M -2.05M -1.94M -1.76M -3.29M -227M -3.32M -23.11M -8.91M -115M -8.89M -8.69M -366M	-2.12M -1.84M -1.74M -1.57M -2.95M -203M -2.98M -20.73M -7.99M -103M -7.97M -7.8M -328M
Net Debt	1.09M 944K 890K 808K 1.52M 104M 1.53M 10.63M 4.1M 52.95M 4.09M 4M 168M	741K 642K 606K 550K 1.03M 71M 1.04M 7.23M 2.79M 36.02M 2.78M 2.72M 115M

End-of-day quote Other OTC
- ^USD	-